Wells Fargo & Company Cuts Danaher (NYSE:DHR) Price Target to $240.00

Danaher (NYSE:DHR) had its target price decreased by equities researchers at Wells Fargo & Company from $280.00 to $240.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the conglomerate’s stock. Wells Fargo & Company‘s price objective indicates a potential upside of 7.57% from the stock’s previous close.

Other research analysts have also issued reports about the company. Stifel Nicolaus increased their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Scotiabank initiated coverage on Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Jefferies Financial Group lowered their price target on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a research report on Wednesday. Robert W. Baird reduced their price objective on shares of Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating for the company in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $280.57.

Danaher Stock Performance

Danaher stock opened at $223.12 on Thursday. The stock has a fifty day moving average price of $236.09 and a two-hundred day moving average price of $253.66. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher has a 52-week low of $223.00 and a 52-week high of $281.70. The firm has a market capitalization of $161.16 billion, a P/E ratio of 42.58, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. During the same period last year, the company earned $2.09 EPS. As a group, analysts anticipate that Danaher will post 7.5 EPS for the current fiscal year.

Institutional Trading of Danaher

A number of hedge funds have recently made changes to their positions in DHR. Root Financial Partners LLC acquired a new position in shares of Danaher in the fourth quarter valued at $343,000. Figure 8 Investment Strategies LLC acquired a new position in shares of Danaher in the fourth quarter valued at approximately $2,102,000. Vontobel Holding Ltd. increased its stake in shares of Danaher by 1.2% during the fourth quarter. Vontobel Holding Ltd. now owns 172,231 shares of the conglomerate’s stock worth $39,536,000 after purchasing an additional 2,094 shares during the period. Bogart Wealth LLC lifted its holdings in Danaher by 11.2% during the 4th quarter. Bogart Wealth LLC now owns 37,548 shares of the conglomerate’s stock worth $8,619,000 after purchasing an additional 3,783 shares during the last quarter. Finally, York GP Ltd. bought a new stake in Danaher in the 4th quarter valued at $4,591,000. 79.05% of the stock is owned by institutional investors and hedge funds.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.